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ABSTRACT
This study assessed the antimicrobial resistance of nasopharyngeal pneumococci isolated from children
aged <5 years in day-care centres and orphanages throughout Russia during 2001–2002. Swabs were
collected from 2484 children in 43 day-care centres and eight orphanages in 11 cities of European Russia,
and from 1669 children in 37 day-care centres and three orphanages in eight cities of Asian Russia, with
a total of 1144 and 912 Streptococcus pneumoniae isolates being recovered in European and Asian Russia,
respectively. All macrolide-non-susceptible (MICs 0.5–128 mg ⁄L) and fluoroquinolone-non-susceptible
(ciprofloxacin MICs ‡4 mg ⁄L) isolates were tested for resistance mechanisms and clonal relatedness.
Non-susceptibility rates, by CLSI criteria, were 19.3%, 0.9% and 0.4% for penicillin G, cefotaxime and
amoxycillin–clavulanate, respectively. Resistance to macrolides and lincosamides was also relatively
low, i.e., <7% for clindamycin and 14- and 15-membered macrolides. The highest rates of non-
susceptibility were for tetracycline and co-trimoxazole (52.0% and 64.5%, respectively). No clones
resistant to ciprofloxacin (MICs ‡8 mg ⁄L) were found, but 1.7% of isolates were non-susceptible
(MIC 4 mg ⁄L). No resistance was found to levofloxacin, gemifloxacin, telithromycin or vancomycin.
Pulsed-field gel electrophoresis analysis showed no relationship between ciprofloxacin- and macrolide-
non-susceptible isolates in European and Asian Russia. Resistance among macrolide-resistant isolates
resulted mostly from the presence of erm(B) and mef(A), and from changes in L4; additionally, L22
mutations were common in isolates from Asian Russia. Non-susceptibility to quinolones was associated
with mutations in parC and parE among European isolates. Asian Russian isolates had mutations in parC
and gyrA, and alterations in parE were more common. There were substantial differences in non-
susceptibility and mechanisms of resistance between pneumococci from Asian and European Russia,
with orphanages appearing to be ‘hot-spots’ of resistance.
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INTRODUCTION
Streptococcus pneumoniae is one of the leading
bacterial pathogens and causes a variety of
community-acquired infections among different
populations. Children aged <2 years, adults aged
>65 years and individuals at risk for community-
acquired respiratory tract infection are at high
risk for colonisation by S. pneumoniae, with poss-
ible subsequent development of infection. For
example, in the USA, there are c. 5 000 000 cases
of otitis media, 13 000 cases of bacteraemia, 700
cases of meningitis and 71 000 cases of pneu-
monia caused by pneumococci recorded annually
in children [1]. Data from the Russian Federation
are not consistent, but it has been estimated that
the annual rate of pneumonia in adults is c. 1.5
million cases, most of which are probably caused
by pneumococci [2].
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Until the 1960s, b-lactams were used widely for
the treatment of pneumococcal infections because
of the then universal susceptibility of S. pneumo-
niae, and because of the belief that streptococci
did not possess mechanisms for the development
of clinically significant resistance. However, there
has clearly been an under-evaluation of the
adaptive and evolutionary capabilities of Strepto-
coccus spp. [3]. Since the first description of
penicillin-resistant pneumococci in Boston in
1965, and especially during the last decade, the
problem of pneumococcal resistance has become
widespread and a cause for concern [4]. Surveil-
lance of pneumococcal resistance among naso-
pharyngeal isolates from children has been found
to be a practical and useful way of estimating the
prevalence of resistant isolates in a community,
and to predict reliably the development of pneu-
mococcal resistance in clinical infections [5–7]. In
addition, carriage of resistant isolates of potential
respiratory pathogens (e.g., S. pneumoniae and
Haemophilus influenzae) has been found to be
associated with previous use of antibiotics, which
may be a risk-factor for the development of
infection [8,9].
There are insufficient data available concerning
the epidemiology of pneumococcal infections,
among both children and adults, in the Russian
Federation. Most studies differ in their approach to
identification and do not address the regional
features of the epidemiological situation [10]. In
addition, susceptibility testing methods used in
many studies do not permit comparisons with the
data published in peer-reviewed publications,
because of insufficient harmonisation of the meth-
odologies used, and because internationally recog-
nised susceptibility testing methods are not
available. Therefore, the present prospective study
had the following objectives: (i) to determine the
carriage rates and antimicrobial resistance pheno-
types of S. pneumoniae isolates from healthy chil-
dren from day-care centres (DCCs) and
orphanages in geographically distinct areas of
Russia, including the central, north-western and
southern regions, Bashkotorstan, Tatarstan, Ural,
Siberia and the Far East; (ii) to perform serotyping
and molecular characterisation of macrolide and
quinolone resistance determinants; and (iii) to
determine the genetic relatedness among 130 iso-
lates that were non-susceptible to erythromycin
(MICs 0.5–128 mg ⁄L) and 35 isolates that were
non-susceptible to ciprofloxacin (MICs ‡4 mg ⁄L).
MATERIALS AND METHODS
The study protocol, the case report form and the procedure for
obtaining informed consent were approved by the Independ-
ent Ethical Committee of the Smolensk State Medical Academy
(Protocol No. 47; 07.02.2001). Written informed consent was
obtained from the parents or legal representatives of the
children involved in the study. The same team, including a
physician and a microbiologist, collected nasopharyngeal
specimens, using calcium alginate swabs (COPAN Diagnos-
tics, Brescia, Italy), from children aged <5 years in institutions
in 19 cities of both European Russia (ER) and Asian Russia
(AR), throughout 2001–2002, via a series of point-prevalence
studies. According to the administrative ⁄ geographical division
of the Russian Federation, 11 of these cities were in ER
(Moscow, Saint Petersburg, Smolensk, Voronezh, Krasnodar,
Volgograd, Nizhniy Novgorod, Kazan, Ufa, Yekaterinburg,
Chelyabinsk) and eight were in AR (Tyumen, Khanty-
Mansiysk, Novosibirsk, Irkutsk, Yakutsk, Anadyr, Khabar-
ovsk, Vladivostok) (Fig. 1). Immediately after collection, the
swabs were plated on Columbia blood 5% v ⁄v agar (bio-
Me´rieux, Marcy l’Etoile, France) containing gentamicin (Sig-
ma, St Louis, MO, USA) 5 mg ⁄L. The plates were then
transported to the local laboratory, with minimal temperature
variations, within 2 h of collection, where they were incubated
at 35C in CO2 3–5% v ⁄v for 24 h. S. pneumoniae was identified
on the basis of colony morphology, susceptibility to optochin
(bioMe´rieux) and a tube test of bile solubility using sodium
deoxycholate 10% v ⁄v (Sigma) [11]. After identification, all
isolates were immediately shipped on Dorset Egg medium to
the central testing laboratory in Smolensk for susceptibility
testing. All isolates non-susceptible to erythromycin
(MICs 0.5–128 mg ⁄L) or ciprofloxacin (MICs ‡4 mg ⁄L) were
then sent on Dorset Egg medium to Hershey Medical Center,
PA, USA, for serotyping and molecular analysis.
Susceptibility to penicillin G, amoxycillin, amoxycillin–
clavulanate, cefotaxime, erythromycin A, azithromycin,
clarithromycin, clindamycin, telithromycin, ciprofloxacin, lev-
ofloxacin, gemifloxacin, tetracycline, co-trimoxazole and
vancomycin was determined using the CLSI (formerly
NCCLS) broth microdilution method [12]. Breakpoints were
those recommended by the CLSI, except for telithromycin
(£0.5, 1–2 and >2 mg ⁄L for susceptible, intermediately-resist-
ant and resistant isolates, respectively) and ciprofloxacin (£2, 4
and ‡8 mg ⁄L for susceptible, intermediately-resistant and
resistant isolates, respectively). As there are no approved
ciprofloxacin breakpoints for pneumococci, the study arbitrar-
ily used those approved by the CLSI for levofloxacin [12]. It
was recognised that, according to current CLSI criteria, isolates
may be resistant to penicillin G, but susceptible to amoxycillin,
with or without clavulanate [12].
The relationship among all macrolide-non-susceptible
(erythromycin MICs 0.5 and ‡1 mg ⁄L for intermediately-
resistant and resistant isolates, respectively) and all quino-
lone-non-susceptible (ciprofloxacin MICs ‡4 mg ⁄L) isolates
was examined by capsular serotyping and by pulsed-field
gel electrophoresis (PFGE) following digestion of genomic
DNA with SmaI [13]. Electrophoresis was performed at
6.6 V ⁄ cm for 16 h, with a pulse time of 5–20 s, in a
CHEF DR III apparatus (Bio-Rad, Hercules, CA, USA). Ana-
lysis of SmaI macrorestriction profiles was performed accord-
ing to currently accepted criteria [14]. The following S. pneu-
moniae clones, which are distributed worldwide, were
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included in the molecular typing analysis: a multidrug-
resistant Spanish ⁄USA isolate of serotype 23F (Spain23F-1)
[15,16]; and penicillin-resistant French ⁄ Spanish isolates of
serotypes 9V (Spain9V-3) and 14 (variant of Spain9V-3) [15].
Serotyping was performed using the standard Quellung
method with a Pneumotest antisera panel (Statens Serum
Institute, Copenhagen, Denmark). Among 140 macrolide-non-
susceptible isolates (erythromycin-resistant and intermedi-
ately-resistant isolates), 130 were analysed for resistance
mechanisms as described previously [17]. Ten isolates were
lost or did not survive transportation. The presence of the
erm(B), erm(A) and mef(A) genes was investigated by PCR. The
oligonucleotide primers used for erm(B) and mef(A) amplifica-
tion have been described previously [17]. For erm(A) amplifi-
cation, the following primers were used: LP1, 5¢-
GCATAAGGAGGAGTTAAA-3¢ (positions 1–18 of the Strep-
tococcus pyogenes ermTR gene) [18], and LP2, 5¢-AT-
CTTCTTTATTGATATTCG-3¢ (positions 306–287), resulting in
a 306-bp amplicon, and LP1 and ermTRrev, 5¢-
TTGGATAATTTATCAAGATCAG-3¢ (positions 896–875),
resulting in a 896-bp amplicon. All erythromycin-non-suscept-
ible isolates that were negative for erm(B) and mef(A) were
screened for the presence of mutations in ribosomal proteins
L4 and L22 and in 23S rRNA as described previously [19].
Quinolone resistance mechanisms were determined for ci-
profloxacin-non-susceptible isolates (MICs ‡4 mg ⁄L). The
quinolone resistance-determining regions (QRDRs) in gyrA,
gyrB, parC and parE were amplified and sequenced as
described previously [13].
All statistical analyses were performed using SAS statistical
software v.6.12 (SAS Institute, Cary, NC, USA). For statistical
comparison, isolates intermediately- and fully-resistant to
penicillin G were combined in the same group. The level of
statistical significance for all comparisons was set at p <0.05.
Categorical values were compared using the chi-square and
Fisher’s exact tests.
RESULTS
Pneumococcal carriage in Russia and resistance
to antimicrobial agents
In total, 4153 children from 91 DCCs and orphan-
ages in 19 cities were included in this study.
Average carriage rates were 45.8% and 53.8% in
ER and AR DCCs, respectively, and were signi-
ficantly lower in ER DCCs (p <0.0001). Similarly,
the average carriage rate in ER orphanages was
lower than that in AR orphanages (47.1% and
66.4%, respectively, p <0.0001), and the carriage
rate in both DCCs and orphanages in ER was also
lower than that in both types of institution in AR
(45.7% and 53.8%, respectively, p <0.0001). The
nasopharyngeal carriage rates varied from 11.1%
to 88.5% in different DCCs and orphanages
(mean 49.5%), with 2056 S. pneumoniae isolates
in total.
Of the 2056 isolates, 41.2% were susceptible to
all antibiotics tested, 2.5% were resistant and
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Fig. 1. Centres from which pneumococcal isolates were collected.
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16.8% were intermediately-susceptible to penicil-
lin; 38.2% were susceptible to penicillin, but
resistant to at least one other antimicrobial agent
(Table 1). The highest number of resistant isolates
came from Moscow and Kazan in ER, and from
Khabarovsk and Novosibirsk in AR. Interestingly,
in one city in AR, Khanty-Mansiysk, no isolates
with elevated MICs were obtained. Erythromycin
resistance was found in 6.5% of the isolates, and
3.5% were resistant to clindamycin. Multidrug
resistance (i.e., resistance to three or more antibi-
otics) was seen in 9.7% of the isolates (Table 1).
There was no correlation between the resistance
phenotypes of 13 isolates shown in Table 1 and
the putative resistance mechanisms. However, for
all but three isolates, MICs clustered around the
susceptible breakpoint. This indicates that poss-
ible additional unidentified resistance mecha-
nisms may be involved in the remaining three
isolates.
Significant differences exist between popula-
tions of children in DCCs and orphanages. The
population of orphanages in Russia is very stable,
with all children resident for 24 h, 7 days ⁄week;
in contrast, children in DCCs stay for only 8 h
daily, 5 days ⁄week. Thus, isolates from children
in these different institutions were compared
separately.
S. pneumoniae isolates from DCCs
Nasopharyngeal swabs were collected from 1987
children in 43 DCCs in 11 cities of ER, and from
1553 children in 37 DCCs in eight cities of AR. In
total, 910 and 835 isolates were obtained from
DCCs in ER and AR, respectively. Susceptibility
testing results are summarised in Table 2. Rates of
non-susceptibility were significantly higher
(p <0.05) for penicillin G, azithromycin, clarithro-
mycin, clindamycin, tetracycline and co-trimoxa-
zole in isolates from AR when compared with
isolates from ER. With respect to other antimicro-
bial agents, no statistically significant differences
were found between isolates from AR and ER.
Resistance to macrolides, including 14- and 15-
membered agents, did not exceed 5%; indeed,
<3% of isolates were resistant to clindamycin, and
no resistance to telithromycin was found, either in
ER or AR. No resistance to aminopenicillins
(amoxycillin and amoxycillin–clavulanate) was
found. Based on MIC90 values, the antimicrobial
agent that was most potent against pneumococci
isolated in DCCs in AR was telithromycin
(MIC90 0.03 mg ⁄L), followed by gemifloxacin,
cefotaxime, erythromycin, clarithromycin and
clindamycin (all 0.06 mg ⁄L). The most potent
antimicrobial compounds against pneumococci
isolated in DCCs in ER, based on the same
criteria, were amoxycillin ± clavulanate, clarith-
romycin and telithromycin (0.03 mg ⁄L), followed
by erythromycin, penicillin G, gemifloxacin and
clindamycin (0.06 mg ⁄L). The least potent com-
pounds in both AR and ER were co-
trimoxazole (MIC90 4 mg ⁄L) and tetracycline
(MIC90 32 mg ⁄L). All isolates were susceptible
to vancomycin (MICs £0.5 mg ⁄L).
Table 1. Antibiotic resistance patterns of pneumococcal
isolates (n = 2056)
PEN R, CLI, ERY, AZI, CLA, TET, COT 11
PEN R, AMO, CLI, ERY, AZI, CLA, TET, COT 1
PEN R, CLI, ERY, AZI, CLA, TET 9
PEN R, CLI, ERY, AZI, CLA, COT 2
PEN R, ERY, AZI, CLA, TET, COT 1
PEN R, ERY, AZI, CLA, TET 13
PEN R, CLI, ERY, AZI, TET 1a
PEN R, ERY, AZI, CLA, COT 1
PEN R, ERY, AZI, CLA 2
PEN R, TET, COT 3
PEN R, TET 1
PEN R, COT 1
PEN R 5
PEN I, CLI, ERY, AZI, CLA, TET, COT 25
PEN I, CLI, ERY, AZI, CLA, TET 1
PEN I, ERY, AZI, CLA, TET, COT 11
PEN I, CLI, ERY, AZI, TET, COT 1a SIG
PEN I, ERY, AZI, CLA, TET 3
PEN I, ERY, AZI, CLA, COT 2
PEN I, ERY, AZI, TET, COT 2a
PEN I, ERY, AZI, CLA 1
PEN I, ERY, AZI, TET 2a
PEN I, ERY, TET, COT 1a
PEN I, AZI, TET 1
PEN I, ERY, COT 1a
PEN I, ERY, TET 1a
PEN I, TET, COT 60
PEN I, TET 171
PEN I, COT 14
PEN I 49
CLI, ERY, AZI, CLA, TET, COT 5
CLI, ERY, AZI, CLA, TET 15
CLI, ERY, AZI, TET, COT 1a SIG
ERY, AZI, CLA, TET, COT 6
ERY, AZI, CLA, TET 8
CLI, ERY, AZI, CLA 1
ERY, AZI, CLA 2
ERY, AZI, TET 1a SIG
ERY, TET, COT 1a
CLI, AZI, TET 1
ERY, AZI 1
ERY, CLA 1a
AZI, TET 1
TET, COT 226
TET 401
COT 114
Susceptible to all antibiotics 874
aIsolates with phenotypes that did not correlate with the putative resistance
mechanisms.
SIG, isolates with phenotypes that did not correlate with the putative resistance
mechanisms and with MICs significantly different from breakpoints.
PEN, penicillin; AMO, amoxycillin; ERY, erythromycin; AZI, azithromycin; CLA,
clarithromycin; CLI, clindamycin; TET, tetracycline; COT, co-trimoxazole; I,
intermediately-resistant; R, resistant.
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Serotyping and molecular typing of
non-susceptible isolates from DCCs
Among 130 macrolide-non-susceptible isolates
(erythromycin MICs ‡1 and 0.5 mg ⁄L), 64 were
from DCCs (38 from AR DCCs and 26 from ER
DCCs). The correlation between PFGE types and
serotypes for these isolates is presented in
Table 3. Isolates from ER and AR DCCs had 15
and 26 distinct PFGE patterns, respectively.
Examples of the PFGE patterns obtained are
shown in Fig. 2. The most common patterns for
ER isolates were patterns B, D, AA, U and Z,
represented by seven, three, two, two and two
isolates, respectively. Pattern F was found in only
one isolate. None of the PFGE patterns matched
those of the three international clones used in this
study.
The serotypes found most frequently among
macrolide-non-susceptible isolates in ER DCCs
were serogroup ⁄ serotype 19 (12 isolates; four
19A, four 19C, one 19C ⁄ F and three 19F), sero-
group ⁄ serotype 6 (five isolates; one 6A and four
6B), serogroup ⁄ serotype 23B (four isolates) and
serogroup ⁄ serotype 14 (three isolates). The
remaining two isolates belonged to sero-
group ⁄ serotypes 3 and 8 (Table 3). Capsular
switching was observed for all isolates with the
PFGE patterns shown in Table 3. Macrolide non-
susceptibility of isolates from ER DCCs was
associated with the presence of erm(B) (16 iso-
lates), mef(A) (three isolates), multiple alterations
in the ribosomal protein L4 (five isolates), or
substitutions in L4 (S20N) and L22 (A105V), or in
L22 and 23S rRNA (each combination occurred in
one isolate). The substitution A105V in L22 has, to
our knowledge, not been described previously,
and was associated with an erythromycin MIC of
2 mg ⁄L (Table 4).
PFGE types K, Q and T, represented by two
isolates each, were most common among isolates
from AR DCCs. The other 23 isolates had unique
PFGE patterns. No PFGE pattern of a Russian
isolate matched that of any of the three interna-
tional clones, and no capsular switching was
observed. Among AR DCC isolates, sero-
group ⁄ serotype 19 was found most frequently
(12 isolates; four 19A, one 19C, three 19C ⁄ F and
four 19F), followed by serogroup ⁄ serotype 23
(three isolates; one 23B, two 23F), serogroup ⁄ ser-
otype 6B (nine isolates), serogroup ⁄ serotype 14
(six isolates) and serogroup ⁄ serotype 18 (three
isolates). The remaining five isolates belonged to
serogroups ⁄ serotypes 9A, 9V, 17 and 22 (Table 3).
Resistance was associated with the presence of
mef(A) (16 isolates), erm(B) (11 isolates), altera-
tions in ribosomal protein L4 (three isolates), and
alterations in L22 and 23S rRNA (one isolate)
(Table 4).
Among 35 isolates that were non-susceptible to
ciprofloxacin, 31 were isolated in DCCs and
distributed almost equally between ER DCCs
and AR DCCs (13 and 18 isolates, respectively).
Ciprofloxacin MICs for these isolates were
4 mg ⁄L, but they remained susceptible to levofl-
oxacin and gemifloxacin (Table 2). There were
nine PFGE types among the 13 ER DCC isolates
(Table 5). Four PFGE types (A, E, G and N) were
represented by two isolates each. Another five
isolates had unique DNA patterns. No PFGE
pattern matched those of the three international
clones used for controls. In isolates with PFGE
Table 2. Non-susceptibility rates
among pneumococci from day-care
centres in Asian and European
Russia
Antimicrobial
agent
Asian Russia European Russia
p% I (n) % R (n) % NS (n) % I (n) % R (n) % NS (n)
Penicillin G 13.7 (114) 0.2 (2) 13.9 (116) 9.0 (82) 0.6 (5) 9.6 (87) 0.006
Amoxycillin 0 0 0 0 0 0 ND
Amoxycillin–
clavulanate
0 0 0 0 0 0 ND
Cefotaxime 0.1 (1) 0 0.1 (1) 0.3 (3) 0 0.3 (3) 0.63
Erythromycin A 0.2 (2) 4.7 (39) 4.9 (41) 0.6 (5) 3.1 (28) 3.7 (33) 0.19
Azithromycin 0.5 (4) 4.6 (38) 5.1 (42) 0.2 (2) 3.2 (29) 3.4 (31) 0.01
Clarithromycin 0.6 (5) 4.6 (38) 5.2 (43) 0.9 (8) 1.9 (17) 2.8 (25) 0.013
Clindamycin 0.1 (1) 2.2 (18) 2.3 (19) 0 0.8 (7) 0.8 (7) 0.01
Telithromycin 0 0 0 0 0 0 ND
Ciprofloxacin 2.2 (18) 0 2.2 (18) 1.4 (13) 0 1.4 (13) 0.6
Levofloxacin 0 0 0 0 0 0 ND
Gemifloxacin 0 0 0 0 0 0 ND
Tetracycline 5.2 (43) 48.0 (401) 53.2 (444) 3.9 (35) 38.8 (353) 42.7 (388) <0.0001
Co-trimoxazole 43.7 (365) 22.3 (186) 66.0 (551) 39.5 (359) 21.0 (191) 60.5 (550) 0.017
R, resistant; I, intermediately-resistant; NS, non-susceptible (defined as resistant and intermediately-resistant
categories); two-sided p value was calculated for NS category; ND, no significant difference.
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Table 3. Correlation between pulsed-
field gel electrophoresis (PFGE)
patterns and serotypes among macro-
lide-non-susceptible pneumococci
from Russia
Isolate
No. of
isolates
PFGE
pattern Serotypes City of isolation
7070, 6676 2 AA 19A, 23B Voronezh
944, 6159, 938, 6153,
1020, 6205, 6173
7 B 19A, 19F, 14 (2)a, 23B (3) Chelyabinsk (6),
Yekaterinburg
1649, 1650, 1667, 1657 4 C 19C (2), 6A, 6B Ufa
704, 705, 658, 662,
663
5 D 19C (3), 19A, 8 St Petersburg (4),
Voronezh
707 1 E1 15 St Petersburg
1638, 1617, 1641 3 F 6B (2), 19A Ufa (3)
376, 272, 420, 430,
352
5 G 19A, 19F (3), 23F Khabarovsk (5)
395, 401, 439 3 I 19C, 23F, 23B Khabarovsk (3)
1394, 1408, 1410, 1411,
1429, 1491, 1430
7 K 6B (7) Novosibirsk (7)
2310, 2311, 2312, 2313,
2383, 2385, 2386, 2399
8 O 19C (8) Kazan (8)
2412, 2422, 2458, 2423,
2468, 2470
6 P 19C (6) Moscow (6)
7288, 7289, 7290, 7292,
7293, 7295
6 Q 14 (6) Irkutsk (6)
2434, 2437, 2435, 2440,
2441, 2450, 2447, 2452
8 R 19A (7), 19C Moscow (8)
2463, 2464, 2465, 2475,
2466, 2469, 2477, 2479,
2492, 2493, 2494
11 S 19A (10), 19C Moscow (11)
7249, 7257 2 T 19C ⁄ F (2) Anadyr (2)
6236, 6237 2 U 19C ⁄ F, 14 Yekaterinburg (2)
7389, 7402 2 X 19C (2) Moscow (2)
6543, 6541, 6542 3 Y 19C, 23F (2) Ufa (3)
6624, 6626 2 Z 6B, 19C Moscow
447, 7275, 6116, 2086,
85, 77, 6006, 6057,
416, 1034, 1350, 154,
2438, 2410, 2233, 280,
1458, 5960, 320, 1188,
789, 785, 5962, 400,
84, 2156, 1454, 6122,
1426, 6342, 5249, 7052,
6289, 6574, 7127, 5969,
6056, 6114, 7132, 7420,
2473, 1401
43 Unique 3, 17, 18 (3), 22 (2),
19A (6), 19F (10), 19C (2), 19C ⁄ F,
23B (2), 23F (5), 6A, 6B (6),
9A, 9V,
non-typeable
19 from European Russia,
28 from Asian Russia
aNumbers in parentheses indicate the number of isolates if >1.
123AA 1JHHGGN 132 2E1E DD321BBIIH321
Fig. 2. Examples of PFGE profiles for antibiotic-non-susceptible pneumococci isolated from day-care centres and
orphanages in Russia. Three international clones, Spain23F-1 (1), Spain9V-3 (2) and a variant of clone Spain9V-3 (3), are
shown for comparison. Isolates with PFGE profile A correspond to serotype 19A; profile N to serotype 6A; profile G to
serotypes 12, 19A, 19F and 23F; profile H to serotype 23B; profile J to serotypes 6A and 6B; profiles E1 and E2 to serotype 15;
profile I to serotypes 19C, 23B and 23B; profile B to serotypes 14, 19A and 23B; and profile D to serotypes 8, 19A and 19C.
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pattern G (Table 5, Fig. 2), capsular switching was
observed.
Serogroups ⁄ serotypes 6A and 15 were repre-
sented by three isolates each. Serogroups ⁄ sero-
types 19A, 23F, 33, 12 and 5 were represented by
one or two isolates. Quinolone-non-susceptible
isolates from ER DCCs possessed alterations in
ParC (one isolate), ParE (four isolates) or ParC
and ParE (one isolate), but seven isolates had no
changes in their QRDRs (Table 6).
Fourteen PFGE patterns were distinguished
among 18 quinolone-non-susceptible isolates
from AR DCCs. Four PFGE patterns (H, J, L and
M) were represented by two isolates. One isolate
had pattern E1, and another nine isolates had
unique patterns. No PFGE pattern matched the
profiles of the three international clones. For
isolates with PFGE patterns J and L (Table 5,
Fig. 2), serotype switching was characteristic.
Serotyping of quinolone-non-susceptible iso-
lates in AR DCCs showed that serogroups ⁄ sero-
types 23 (seven isolates; four 23B and three 23F),
6B (four isolates; two 6A and two 6B) and 19 (four
isolates; three 19A and one 19F) were the most
common. Three isolates belonged to sero-
groups ⁄ serotypes 12, 14 or 15. The resistance
mechanisms in AR DCC isolates mostly involved
alterations in ParE (ten isolates, four of which had
double or triple ParE changes), or in ParE and
ParC (three isolates). A change in GyrA was
observed in one isolate. Four isolates had no
alterations in their QRDRs (Table 6).
S. pneumoniae isolates from orphanages
Nasopharyngeal swabs were collected from 497
children in eight orphanages in six cities of ER,
and from 116 children from three orphanages in
Table 4. Mutations detected among macrolide-non-susceptible, erm(B)-, erm(A)- and mef-negative pneumococci from
Russia
Isolate City Institution L4 L22 23S rRNA
704 St Petersburg Orphanage no. 12 E13Q, S20N, E30Q, 69GTG71-TPS, V88I, G88A, A128S, S130K – –
705 St Petersburg DCC no. 133 69GTG71-TPS – –
658 St Petersburg Orphanage no. 12 69GTG71-TPS – –
662 St Petersburg DCC no. 17 69GTG71-TPS – –
663 Voronezh DCC no. 175 69GTG71-TPS – –
395 Khabarovsk Orphanage no. 2 S20N, TPS – –
401 Khabarovsk Orphanage no. 2 S20N, TPS – –
439 Khabarovsk Orphanage no. 2 S20N, TPS – –
2310 Kazan Orphanage no. 2 E13Q, S20N, E30Q, 69GTG71-TPS, V88I, G88A, A128S, S130K – –
2311 Kazan Orphanage no. 2 E13Q, S20N, E30Q, 69GTG71-TPS, V88I, G88A, A128S, S130K – –
2312 Kazan Orphanage no. 2 E13Q, S20N, E30Q, 69GTG71-TPS, V88I, G88A, A128S, S130K – –
2313 Kazan Orphanage no. 2 E13Q, S20N, E30Q, 69GTG71-TPS, V88I, G88A, A128S, S130K – –
2383 Kazan Orphanage no. 2 E13Q, S20N, E30Q, 69GTG71-TPS, V88I, G88A, A128S, S130K – –
2385 Kazan Orphanage no. 2 E13Q, S20N, E30Q, 69GTG71-TPS, V88I, G88A, A128S, S130K – –
2386 Kazan Orphanage no. 1 E13Q, S20N, E30Q, 69GTG71-TPS, V88I, G88A, A128S, S130K – –
2399 Kazan Orphanage no. 1 E13Q, S20N, E30Q, 69GTG71-TPS, V88I, G88A, A128S, S130K – –
2422 Moscow Orphanage no. 2 S20N – –
2423 Moscow Orphanage no. 2 S20N – –
2468 Moscow Orphanage no. 24 S20N – –
2470 Moscow Orphanage no. 24 S20N – –
7127 Smolensk DCC ‘Glade’ S20N A105V –
5969 Khabarovsk Orphanage no. 2 S20N – –
6056 Yakutsk DCC no. 16 S20N – –
6114 Yakutsk DCC no. 10 S20N – –
7132 Smolensk DCC ‘Campanula’ S20N – –
7420 Moscow Orphanage no. 2 S20N – –
2473 Moscow Orphanage no. 24 S20N – –
1401 Novosibirsk DCC no. 449 S20N – –
7389 Moscow Orphanage no. 2 S20N – –
5962 Khabarovsk Orphanage no. 2 L110F – –
400 Khabarovsk Orphanage no. 2 – K8I G2146A
84 Tyumen DCC no. 158 – K8I G2548T
707 St Petersburg Orphanage no. 12 – – –
2156 Irkutsk DCC no. 28 – – –
1454 Novosibirsk DCC no. 304 – – –
6122 Yakutsk DCC no. 26 – – –
1426 Novosibirsk DCC no. 234 – – –
6342 Novosibirsk DCC no. 449 – – –
273 Khabarovsk DCC no. 167 – – –
5249 Khabarovsk DCC no. 130 – – –
7052 Volgograd DCC no. 387 – – –
6289 Ekaterinburg DCC no. 43 – – –
DCC, day-care centre.
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two cities of AR. In total, 234 and 84 isolates were
obtained from orphanages in ER and AR, respect-
ively. Susceptibility testing results are summa-
rised in Table 7. The rates of non-susceptibility to
penicillin G and clindamycin in ER were statisti-
cally higher than those in AR (p <0.05), but non-
susceptibility to co-trimoxazole was more fre-
quent in AR (p <0.0001). There were no statisti-
cally significant differences between the rates of
resistance to other antimicrobial agents in isolates
from AR and ER. Among the b-lactams, amino-
penicillins (amoxycillin ± clavulanate) and cefo-
taxime had the highest in-vitro activity.
Macrolides, including 14- and 15-membered
agents, possessed moderate in-vitro activity
against the isolates tested, with resistance rates
being in the range of 17–24%. Clindamycin
resistance was found in 7.8% of isolates from
AR and in 18.4% from ER. No resistance to
telithromycin was found in either ER or AR.
Based on MIC90 values, the antimicrobial
agents with the most potent activity against
pneumococci isolated from children in orphan-
ages in AR were gemifloxacin and telithromycin
Table 5. Correlation between pulsed-
field gel electrophoresis (PFGE)
patterns, serotypes and resistance
mechanisms among quinolone-
non-susceptible pneumoccoci from
Russia
Isolate No. of isolates PFGE profile Serotypes City of isolation
1686, 1690 2 A 19 A (2)a Moscow (2)
234, 668, 1341 3 E (E1, E2, E3) 15 Voronezh, St Petersburg,
Vladivostok
1059, 1105 2 G 23F, 12 Yekaterinburg (2)
286, 288 2 H 23B (2) Khabarovsk (2)
96, 98 2 J 6A, 6B Tyumen (2)
1434, 1438 2 L 23F, 23B Novosibirsk (2)
2024, 2065 2 M 19A (2) Anadyr (2)
1071, 1092 2 N 6A (2) Yekaterinburg (2)
1180, 1368, 391, 1006,
102, 264, 544, 644,
711, 1242, 79, 94,
302, 387, 415, 832,
893, 2306
18 Unique 5, 6, 12, 14 (2),
15, 33, 19A (2),
19F, 23B, 23F (3), 6A (2),
6B (2)
8 from European Russia,
10 from Asian Russia
aNumbers in parentheses indicate the number of isolates if >1.
Table 6. Resistance mechanisms
among quinolone-non-susceptible
pneumococci from Russia
Isolate City Institution
gyrA
mutations
gyrB
mutations
parC
mutations
parE
mutations
668 Voronezh DCC no. 188 – – K137N –
286 Khabarovsk DCC no. 167 – – K137N V461I
288 Khabarovsk DCC no. 167 – – K137N V461I, V488A
391 Khabarovsk DCC no. 139 – – K137N 460IV SUBST 460VA, A466D
1006 Yekaterinburg DCC no. 102 – – – V461I
1438 Novosibirsk DCC no. 234 – – – V461I
102 Tyumen DCC no. 172 – – – 460IV SUBST 460VA, A466D
79 Tyumen DCC no. 172 – – – V461I
94 Tyumen DCC no. 172 – – – V461I
96 Tyumen DCC no. 111 – – – V461I
98 Tyumen DCC no. 111 – – – V461I
1180 Smolensk Orphanage – – K137N –
1341 Smolensk DCC ‘Campanula’ – – – –
1368 Smolensk DCC ‘Campanula’ – – – –
1686 Moscow DCC no. 1892 – – – –
1690 Moscow DCC no. 1892 – – – –
2024 Anadyr DCC no. 2 – – – –
2065 Anadyr DCC no. 2 – – – –
234 Vladivostok DCC no. 39 – – – –
264 Vladivostok DCC no. 111 – – – –
544 Volgograd Orphanage – – – –
644 St Petersburg DCC no. 70 – – – –
711 St Petersburg DCC no. 70 – – – –
1242 Smolensk DCC ‘Glade’ – – – –
302 Khabarovsk DCC no. 130 A147G – – –
387 Khabarovsk Orphanage no. 1 – – – V461I
415 Khabarovsk DCC no. 167 – – – V461I
832 Yakutsk DCC no. 86 – – – 460IV SUBST 460VI
893 Yakutsk DCC no. 86 – – – V461I
1059 Yekaterinburg DCC no. 102 – – – V461I
1071 Yekaterinburg DCC no. 102 – – – V461I
1092 Yekaterinburg DCC no. 102 – – K137N V461I, V488A
1105 Yekaterinburg DCC no. 102 – – – V461I
1434 Novosibirsk DCC no. 234 – – – V461I
2306 Kazan Orphanage no. 2 – – – –
DCC, day-care centre.
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(MIC90 0.03 mg ⁄L), followed by clindamycin
(0.25 mg ⁄L) and amoxycillin and amoxycillin–
clavulanate (0.5 mg ⁄L). The most potent anti-
microbial agents against isolates from ER were
gemifloxacin (0.03 mg ⁄L), telithromycin (0.12
mg ⁄L) and cefotaxime (0.5 mg ⁄L). The least
potent compounds against both AR and ER
isolates were co-trimoxazole and tetracycline.
Serotyping and molecular typing of
non-susceptible isolates from orphanages
In total, 66 macrolide-non-susceptible isolates
were obtained from children in orphanages and
characterised further; 53 were from ER orphan-
ages and 13 from AR orphanages. Eleven different
PFGE profiles were observed among the ER
orphanage isolates. Profiles C, O, P, R, S and Y
were seen in four, eight, six, eight, 11 and three
isolates, respectively. Patterns D, E1, F and X were
seen in one or two isolates. PFGE pattern E1 was
seen in one isolate (Table 3). Three additional
isolates belonged to the same PFGE profile, but
were quinolone non-susceptible and isolated in
DCCs from ER and AR (Table 5). Six isolates
showed unique patterns (Table 3). No PFGE
profile matched the profiles of the three interna-
tional clones used as controls. Serotype switching
was observed in isolates of PFGE profiles C, D, F,
R, S and Y (Fig. 2), although among isolates with
profiles R and S, the switch was observed within
serotype 19 (Table 3).
Serogroups ⁄ serotypes 19 (42 isolates; 19 19A, 22
19C and one 19F), 23 (five isolates; one 23B and
four 23F) and 6 (four isolates; one 6A and three
6B) were the most common serotypes found
among quinolone-non-susceptible isolates in ER
orphanages. Serogroup ⁄ serotype 15 was repre-
sented by one isolate, and one isolate was
non-typeable (Table 3). Resistance among macro-
lide-non-susceptible isolates from ER orphanages
was mostly caused by the presence of mef(A) (21
isolates), erm(B) (13 isolates) or alterations in
ribosomal protein L4 (17 isolates). One strain
from ER (a St Petersburg orphanage) possessed
the erm(A) gene. The mechanism(s) of resistance
in one isolate remains unknown (Table 4).
Seven PFGE patterns were distinguished
among isolates from children in AR orphanages.
Patterns G and I (Fig. 2) were represented by five
and three isolates, respectively. Capsular switch-
ing was observed among all isolates with these
patterns. The remaining five isolates had unique
PFGE profiles (Table 3). No PFGE pattern
matched the profile of the three international
clones. Serotype 19 (eight isolates; one 19A, one
19C and six 19F) was encountered most com-
monly. Serotype 23 was represented by four
isolates (one 23B and three 23F) and serotype 6B
by one isolate. Macrolide resistance was caused
by erm(B) (six isolates), mef(A) (one isolate) or
alterations in ribosomal protein L4 (five isolates)
or L22 and 23S rRNA (one isolate) (Table 4).
Among 35 ciprofloxacin-non-susceptible iso-
lates, four were isolated in ER and AR orphanages
(three and one, respectively). The MIC of cipro-
floxacin for all isolates was 4 mg ⁄L, but they
remained susceptible to levofloxacin and gemi-
floxacin (Table 7). One isolate from an AR
orphanage had a rare PFGE profile, belonged to
serotype 6B, and had an alteration in ParE
(Tables 5 and 6). Three isolates from ER orphan-
ages had unique PFGE profiles, and were of
serotypes 6B, 19A and 14; only one isolate had an
Table 7. Non-susceptibility rates
among pneumococci isolated from
children in orphanages in Asian and
European Russia
Antimicrobial
agent
Asian Russia European Russia
p% I (n) % R (n) % NS (n) % I (n) % R (n) % NS (n)
Penicillin G 33.8 (26) 9.1 (7) 42.9 (33) 53.0 (124) 15.8 (37) 68.8 (161) <0.0001
Amoxycillin 1.3 (1) 0 1.3 (1) 2.1 (5) 0.4 (1) 2.5 (6) 1.0
Amoxycillin–
clavulanate
1.3 (1) 0 1.3 (1) 2.1 (5) 0.4 (1) 2.5 (6) 1.0
Cefotaxime 2.6 (2) 0 2.6 (2) 5.1 (12) 0 5.1 (12) 0.53
Erythromycin A 0 16.9 (13) 16.9 (13) 0.4 (1) 23.5 (55) 23.9 (56) 0.21
Azithromycin 1.3 (1) 16.9 (13) 18.2 (14) 0.4 (1) 23.9 (56) 24.3 (57) 0.35
Clarithromycin 0 18.2 (14) 18.2 (14) 0.9 (2) 22.2 (52) 23.1 (54) 0.43
Clindamycin 1.3 (1) 6.5 (5) 7.8 (6) 0 18.4 (43) 18.4 (43) 0.03
Telithromycin 0 0 0 0 0 0 ND
Ciprofloxacin 1.3 (1) 0 1.3 (1) 1.3 (3) 0 1.3 (3) 1.0
Levofloxacin 0 0 0 0 0 0 ND
Gemifloxacin 0 0 0 0 0 0 ND
Tetracycline 2.6 (2) 77.9 (60) 80.5 (62) 2.1 (5) 73.1 (171) 75.2 (176) 0.44
Co-trimoxazole 31.2 (24) 59.7 (46) 90.9 (70) 37.6 (88) 29.1 (68) 66.7 (156) <0.0001
R, resistant; I, intermediately-resistant; NS, non-susceptible (defined as resistant and intermediately-resistant
combined); two-sided p was calculated for NS category; ND, no difference.
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alteration in ParC, and two isolates had no
changes in their QRDRs (Tables 5 and 6). No
PFGE profile matched the profile of the three
international clones.
DISCUSSION
Rates of antibiotic resistance in pneumococci
among children attending DCCs and orphanages
have been used extensively as a predictor of
resistance in clinical isolates [5–8]. In this study,
the first of its kind covering different regions in a
territory equivalent to one-seventh of the globe,
standardised methodology was used and techni-
cal variations were minimised by the same inves-
tigators both collecting and isolating the bacteria.
In addition, antimicrobial susceptibility testing
was performed at a single centre using standard-
ised CLSI methodology. No study on a similar
scale has been conducted previously in Russia.
Similar studies have been performed in other
countries, but only among children from DCCs
[20–23]. These latter studies had smaller numbers
of children and isolates, as well as different study
designs. In the present study, the rates of carriage
among children from DCCs (mean of 48%) were
comparable with those reported in other countries
[21,23], where carriage values range between 48%
and 54.7%. In two studies conducted in orphan-
ages in Romania and France [24,25], the carriage
rates of 47% and 57.4%, respectively, were lower
than the carriage rates in ER and AR orphanages
combined (mean 59.5%), but similar to those in
ER orphanages when analysed separately (47%).
However, the above studies were conducted in
only one orphanage each, and on a smaller
number of isolates and children.
The antibiotic resistance patterns of the isolates
tested are difficult to compare with other avail-
able data because of differences in study design.
However, in a similar study among children
attending DCCs in Portugal [23], the percentages
of isolates either non-susceptible to penicillin,
resistant to all antibiotics, or susceptible to all
antimicrobial agents tested, were higher (22%,
26% and 60%, respectively). Stratchounski et al.
[10] reported that 7.5% of isolates from DCCs in
ER were intermediately-resistant to penicillin,
and that no isolates were fully-resistant to peni-
cillin. In contrast, the present study found that 9%
of isolates were intermediately-resistant to peni-
cillin, and that 0.6% of isolates from DCCs in ER
had penicillin MICs ‡2 mg ⁄L. However, macro-
lide resistance rates were higher than in the
present study (4.6% and 2.2%, respectively), as
was the mean carriage rate (55.9% vs. 49%). The
pneumococcal population in DCCs seemed to be
unique, but showed some similarities with pop-
ulations in other countries. In ER DCCs the
population is dynamic and changes with time,
so further monitoring is required.
The observed differences in non-susceptibility
rates between DCCs and orphanages suggest that
these two types of childcare institution may
harbour different S. pneumoniae popula-
tions. The rates of resistance to penicillin G,
cefotaxime, tetracycline, co-trimoxazole, clinda-
mycin and 14- and 15-membered macrolides
among pneumococci isolated in orphanages were
higher than those in DCCs, independent of the
geographical location. Non-susceptibility to
ciprofloxacin remained at similar levels, i.e., 1.7%
and 1.3% in DCCs and orphanages, respectively.
The high levels of non-susceptibility to tetra-
cycline (42.7% and 75.2% in DCCs and orphan-
ages in ER vs. 53.2% and 80.5% in DCCs and
orphanages in AR) and to co-trimoxazole (60.5%
and 66.7% in DCCs and orphanages in ER vs.
66.0% and 90.9% in DCCs and orphanages in AR)
considerably exceed those reported previously
among clinical isolates in Russia [26]. This phe-
nomenon is probably related to the fact that these
are the antimicrobial agents found most fre-
quently in the home medicine cabinets of Russian
families who do not consult a practising physi-
cian, indicating frequent and mainly inappropri-
ate self-prescription. Among b-lactam agents,
amoxycillin (with or without clavulanate)
retained the highest in-vitro activity, in both
DCCs and orphanages, with >97% of isolates
remaining susceptible. All isolates remained sus-
ceptible to telithromycin. Higher resistance rates
in orphanages might be caused by the fact that
larger numbers of children are in residence for
24 h, 7 days ⁄week, and that the children are
treated with different levels of care. This may
predispose to the transfer of bacteria among
children [23,24].
Differences were also observed when isolates
from DCCs in ER and AR were compared. In
general, resistance in pneumococci isolated from
children attending DCCs in AR was higher than in
ER, achieving a statistically significant difference
with respect to penicillin G, azithromycin, clarith-
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romycin, clindamycin, tetracycline and co-trim-
oxazole. In contrast, resistance to only penicillin G
and clindamycin was significantly higher, and
resistance to co-trimoxazole was lower, in orphan-
ages in ER compared to AR. A very high level of
resistance to penicillin G was found in ER
orphanages (53% intermediately-resistant and
15.8% highly-resistant isolates), which was signi-
ficantly higher than in AR orphanages (p <0.05).
The reasons for geographical differences in non-
susceptibility rates are unclear, but might be
related to different patterns of antibiotic use in
ER and AR, as well as in orphanages and in DCCs,
and also to higher cross-infection rates in AR than
in ER. The comparatively low prevalence of
resistant pneumococci in ER is similar to that
found in the Baltic States.
Macrolide non-susceptibility in the present
study (defined as erythromycin MICs of 0.5 to
>4.0 mg ⁄L), was associated mainly with erm(B)
and mef(A), as well as mutations in ribosomal
protein L4 (35.1%, 30.6% and 23.1%, respect-
ively). The almost equal distribution of erm(B) and
mef(A) is similar to data from Germany [27], but
differs with findings from Greece, Italy and
Vietnam, where the majority of strains were
erm(B)-positive [20]. The mechanism of resistance
in 8.9% of the present isolates remains unknown.
The proportions of DCC isolates with erm(B),
mef(A) and L4 mutations were 39.7%, 27.9% and
11.8%, respectively. However, in orphanages,
most isolates had mutations in L4 (33.3%), or
harboured mef(A) (33.3%) or erm(B) (28.8%). The
commonest pneumococcal macrolide resistance
mechanisms are mef(A) and erm(B), although
there are regional and geographical differences
in the prevalences of mef(A)- and erm(B)-positive
isolates in different countries [28]. The present
study also revealed differences in macrolide
resistance mechanisms among different childcare
institutions. These differences cannot be ex-
plained by differences in selection pressure or
clonal dynamics [28]. High numbers of isolates
with L4 mutations are unusual, especially in
orphanages. It can be hypothesised that crowding
in orphanages and the presence of children for
24 h ⁄day are major factors facilitating clonal
spread and selection of these macrolide-resistant
isolates.
All isolates with the 69GTG71 ﬁ 69TPS71 sub-
stitution in L4 were highly macrolide-resistant
and belonged to four clonal lineages present in ER
and AR. This substitution has been described
previously [10,17–31], and has been associated
with an increase in the MICs of macrolides. All
isolates with other L4 alterations were character-
ised by unique PFGE patterns and low levels of
resistance to erythromycin (0.5–2 mg ⁄L). These
isolates were from DCCs and orphanages
throughout Russia. Substitution S20N in protein
L4 has been observed in macrolide-resistant
clinical isolates [27,32], but was not found to be
responsible for macrolide resistance. This sug-
gests that substitution 69GTG71 ﬁ 69TPS71
could potentially lead to clones better adapted
to antibiotic pressure and with a propensity to
spread. Additionally, the mutations in protein
L22 and in 23S rRNA (Table 4) which, to our
knowledge, have not been described previously,
were characteristic for isolates from DCCs and
orphanages in Russia, and were associated with
high-level macrolide resistance in isolates with
unique PFGE patterns (Table 6).
Quinolone-non-susceptible isolates either had
changes in ParC (K137N) and ParE (I460V, V461I,
V488A) or had no QRDR alteration. Among AR
isolates, one substitution in GyrA (A147G) was
detected (Table 6), but alterations in ParE were
more common. The substitutions in ParC (K137N)
and in ParE (I460V) have been associated previ-
ously with reduced susceptibility to quinolones
[33]. The GyrA substitution A147G, and the ParE
substitutions V461I, A466D and V488A, have not
yet been reported in clinical isolates.
The quinolone-resistant isolates which had
either QRDR mutations not known to confer
resistance to quinolones or no mutations in this
region, probably had activated efflux system(s)
[34–36] or other, as yet unknown, resistance
mechanisms. Of particular concern were isolates
with a ciprofloxacin MIC of 4 mg ⁄L, which were
isolated mostly in DCCs. Since quinolones are not
used in paediatric medicine, it is possible that
these isolates were acquired from adults, and
represent a possible first step in the development
and further spread of pneumococci with high
levels of quinolone resistance throughout Russia.
However, these isolates retained susceptibility to
levofloxacin and gemifloxacin.
PFGE data confirmed the genetic diversity of
the pneumococci circulating in different cities and
institutions for children in Russia. The interna-
tional clones, Spain9V-3 serotypes 9V and 14, and
Spain23F-1, were chosen as controls because they
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are the clones isolated most frequently in Europe
and North America [15,16]. Surprisingly, there
were no isolates belonging to identical or related
clonal types among the 165 isolates characterised
by PFGE from Russian DCCs or orphanages.
Also, PFGE analysis showed that the majority of
identical PFGE patterns were found in the same
cities, and mostly in the same childcare institu-
tions. Representatives from two PFGE clusters, G
(seven isolates) and E (four isolates), were found
in orphanages and DCCs in AR and ER. These
isolates had different drug susceptibilities. PFGE
type G isolates had different serotypes, while
PFGE type E isolates had the same serotype. This
suggests that the Russian S. pneumoniae popula-
tion may be unique at the present time, with no
intensive circulation of isolates among centres in
both parts of Russia and other countries or
continents. Further monitoring is required to
investigate whether this situation is changing.
Multilocus sequence typing was not performed to
further characterise clones in the current study.
However, in a study of this magnitude, repre-
senting the first study of its kind in the Russian
Federation, it was considered that a combination
of serotyping and PFGE analysis was adequate to
characterise the clones studied.
Among isolates from orphanages, 79% were
grouped in clusters, compared with 49% of DCC
isolates. Clustering was especially high in ER
orphanages (84%). In a previous study from The
Netherlands, Bogaert et al. [21] reported that 75%
of the pneumococci from DCCs formed genetic
clusters, and 50% of these were also found in
populations of children who did not attend DCCs.
Thus, the pneumococcal populations in Russian
DCCs may be genetically similar to those seen in
Dutch children not attending DCCs, while Russian
orphanage pneumococcal populations may be
genetically close to those in Dutch DCCs. This
may also suggest increased spread of pneumococci
in Russian orphanages as compared to DCCs.
Serotyping of all isolates that were non-sus-
ceptible to macrolides and quinolones showed
that, among DCC isolates, the most common were
serogroups ⁄ serotypes 19, 23, 6, 14, 15 and 18.
Isolates from orphanages were mostly of sero-
groups ⁄ serotypes 19, 23 and 6. This probably
reflects a rough correlation among serotypes 6,
9V, 14, 19A, 19F and 23F, which have the potential
to become resistant to antibiotics, as opposed to
other serotypes [37]. Also, serotypes 6, 14, 19 and
23 may be carried for longer periods, and pro-
longed carriage is common in childcare institu-
tions such as DCCs and orphanages. Serotypes
19A, 19F, 23F, 6A, 6B, 9V, 14, 18 and 3 were
detected among carriage isolates in this study.
These serotypes, as well as the routinely isolated
serotypes 15 and 33, are known to be associated
with nasopharyngeal carriage [37]. Serotypes 19C,
23B, 8, 9A, 12, 17 and 22 have not yet been
associated with carriage. The high prevalence of
the rare, non-vaccine, type 19C (6% in Russian
DCCs and 33% in orphanages) is worth noting,
and further monitoring is required. Also, the
presence of four isolates reacting with anti-19C
and anti-19F antisera is interesting and may be
evidence of capsular switching. In the Russian
DCC population, coverage by the heptavalent
conjugated pneumococcal vaccine (PCV-7), cur-
rently licensed in the USA and some European
countries, was 50%, with 20% coverage for
vaccine-related serogroups 19A and 6A. A lower
potential coverage of PCV-7 (30%) was observed
in orphanages, with an additional 31% coverage
for vaccine-related serotypes. It is not known if
cross-protective effects can be expected for vac-
cine-related serotypes 19A and 23B, but this effect
is observed for serotype 6A [21]. These percent-
ages are close to those reported from Asia (50%),
but are much lower than those reported from
North America, Australia, Europe, Africa and
Latin America (65–90%) [36]. However, the latter
studies were focused mostly on penicillin-resist-
ant isolates, but not on macrolide- and quinolone-
non-susceptible isolates.
In conclusion, this prospective multicentre
study provides new data concerning antimicrobial
resistance profiles and the phenotypic and geno-
typic diversity of pneumococci colonising the
nasopharynges of children attending DCCs and
orphanages in both AR and ER. Molecular char-
acterisation of resistance mechanisms provides
new insights into the varying genetic diversity of
the pneumococcal populations that colonise carri-
ers in DCCs and orphanages in Russia. The
S. pneumoniae population in DCCs is more diverse
in terms of resistance patterns, serotypes and
genetic structure than that in orphanages. Also,
carrier populations in Russia differ in terms of
macrolide resistance mechanisms and in serotype
patterns covered by PCV-7. Moreover, the find-
ings suggest that the Russian carrier population is
isolated and that no circulation of common
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S. pneumoniae clones among ER, AR and other
countries has occurred to date. Surveillance stud-
ies of this kind are useful in highlighting
geographical differences, monitoring antibiotic
resistance, and providing new insights into the
course of nasopharyngeal colonisation. Such stud-
ies should be repeated every few years in order to
determine whether a correlation exists between
the incidence of resistant strains among carriers
and that of those isolated from clinical infections.
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